Table 1.

In vitro and in vivo studies with Saporin-S6 (SAP) containing immunotoxins (ITs) targeting hematological tumors.

			Antitumor Activity
Antibody	Target Antigen	Tumor	In vitro IC50 (M)	In vivo		Ref.
				Schedule	Effects
Various	CD2	T-CLL	10−13~10−11	n.d.	n.d.	[8]
OKT11 7A10C9	CD2	T-CLL	<5 × 10−13	n.d.	n.d.	[9]
OKT1	CD5	T-lymphocytes B-CLL	3.2 × 10−10; 4~6.8 × 10−9	n.d.	n.d.	[10,11]
UCHT1	CD3	lymphocytes	2.1 × 10−10	n.d.	n.d.	[6,12]
HB2 × DB7-18	CD7	T-ALL	2.3 × 10−10	n.d.	n.d.	[13,14]
HB2	CD7	T-ALL	4.5 × 10−12	SCID-HSB2 mice; 1 × 0.5 mg/kg	50% survival at 150 days	[15,16]
BU12	CD19	B-LL		SCID-NALM-6 mice; 3 × 10 μg	40% survival at 110 days	[17]
		BL		SCID-Ramos mice; 1 × 10 μg IT + 10 μg Rituximab	100% survival at 120 days	[18,19]
Rituximab	CD20	NHL	1~3 × 10−10	n.d.	n.d.	[20]
F(ab’)2 BsAbs	CD22	BL	1.5~6 × 10−10	n.d.	n.d.	[21]
OM124	CD22	B lymphoblastoid, BL	<5 × 10−15~2.0 × 10−11	SCID-Daudi mice 3 × 0.5 mg/kg 2 × 0.5 mg/Kg IT + 60 mg/Kg cyclophosphamide	33% tumor free 66% tumor free	[22]
Ber-H2	CD30	HD	5 × 10−12~5 × 10−14	n.d.	n.d.	[23]
		ALCL		SCID-JB6 mice 3 × 11.3 μg	CR 80% CR 30%	[24]
		ALCL		SCID-D430B mice 1 × 0.1 mg/kg	CR 66% PR 33%	[25]
IB4	CD38	NHL	2~13 × 10−12	n.d.	n.d.	[26]
B7-24	CD80	BL, HD	<10−11	n.d.	n.d.	[27]
M24 + IG10	CD80/ CD86	BL, HD	0.3~5.8 × 10−12	n.d.	n.d.	[28]
83	CD3/ CD28	lymphocytes	8 × 10−11 AC50 2 × 10−12	n.d.	n.d.	[29]
		ALL	AC50 10−11	n.d.	n.d.	[30]
ATG	various	lymphoma and leukemia cells	5 × 10−11~10−10	n.d.	n.d.	[31]

ALCL: anaplastic large-cell lymphoma; ALL: acute lymphoblastic leukemia; B-CLL; B-chronic lymphocytic leukemia; BL: Burkitt’s lymphoma; B-LL: B-cell lymphoblastic leukemia; CR: complete remission; HD: Hodgkin’s disease; NHL: non-Hodgkin’s lymphoma; PR: partial remission; n.d.: not determined; T-ALL: T-cell acute lymphoblastic leukemia; T-CLL: T-cell chronic lymphocytic lymphoma.